
BYSI — BeyondSpring Inc
NASDAQ · Healthcare · Biotechnology
$0.60
-$0.02 (-2.88%)
BeyondSpring Inc (BYSI) is a biotechnology company listed on NASDAQ. It is led by Lan Huang Ph.D., based in 100 Campus Drive, Florham Park, NJ, United States, 07932, with about 40 employees. BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Net income was -$849.0K. BYSI currently screens at market cap $92.3M.
Use this BYSI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BYSI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BYSI SEC filings page. Lician reads the product cache first so this HTML stays unique to BeyondSpring Inc even when a live quote feed is slow.
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
BYSI Key Statistics
Market Cap
$92.32M
Volume
44,391
Previous Close
$0.71
Day Range
$0.71 – $0.77
EPS
$0.00
Revenue
$0.00
Net Income
-$1.01M
Gross Profit
$0.00
Free Cash Flow
-$19.72M
Debt to Equity
0.00
Employees
40
BYSI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | -$8.95M | -$8.75M |
| Net Income | -$1.01M | -$11.12M |
| EPS (Diluted) | $0.00 | $0.00 |
Total Assets
$25.93M
Total Debt
$0.00
Shareholders' Equity
-$32.16M
Cash & Equivalents
$7.79M
Operating Cash Flow
-$19.77M
Free Cash Flow
-$19.72M
BeyondSpring Inc Company Information
- Co-Founder, Chairman & CEO
- Lan Huang Ph.D.
- Headquarters
- 100 Campus Drive, Florham Park, NJ, United States, 07932
- Website
- beyondspringpharma.com
- Phone
- 646-305-6387
- IPO / Founded
- 2017-03-09
- Sector
- Healthcare
- Industry
- Biotechnology